Genialis, the RNA biomarker company, is creating a world where healthcare delivers the best possible outcomes for patients, their families, and their communities. Genialis develops and validates clinically actionable biomarkers informed by the world’s most ethnographically diverse cancer data sets to better predict patient responses and guide treatment decisions for targeted inhibitors, immunotherapies, and other emerging therapeutic classes. Biomarkers developed by Genialis can improve success and reduce time to market for investigational drugs, identify additional patient subgroups and indications to expand labels of on-market drugs, and power the most informative and precise diagnostics tests to classify patients for treatment.